The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

May. 20, 2016
Applicant:

Chong Kun Dang Pharmaceutical Corp., Seoul, KR;

Inventors:

Changsik Lee, Yongin-si, KR;

Jaekwang Lee, Yongin-si, KR;

Hyeseung Song, Yongin-si, KR;

Daekwon Bae, Yongin-si, KR;

Nina Ha, Yongin-si, KR;

Hyang Kim, II, Yongin-si, KR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 295/215 (2006.01); A61P 37/00 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); C07D 241/04 (2006.01); C07D 471/10 (2006.01); C07D 211/18 (2006.01); C07D 211/22 (2006.01); C07D 211/58 (2006.01); C07D 211/62 (2006.01); C07D 213/36 (2006.01); C07D 295/205 (2006.01); C07D 211/96 (2006.01); C07D 211/54 (2006.01);
U.S. Cl.
CPC ...
C07D 295/215 (2013.01); A61P 9/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 211/18 (2013.01); C07D 211/22 (2013.01); C07D 211/54 (2013.01); C07D 211/58 (2013.01); C07D 211/62 (2013.01); C07D 211/96 (2013.01); C07D 213/36 (2013.01); C07D 241/04 (2013.01); C07D 295/205 (2013.01); C07D 471/10 (2013.01);
Abstract

The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.


Find Patent Forward Citations

Loading…